Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F/TAF in Salvage ART for Resistant HIV
NCT02556333Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: HIV RNA Change From Baseline to Day 10. Started Sep 2015; status: terminated.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02556333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556333.